185 related articles for article (PubMed ID: 30824914)
1. Therapeutic gene editing, making a point.
Smits AM
Cardiovasc Res; 2019 Mar; 115(4):e39-e40. PubMed ID: 30824914
[No Abstract] [Full Text] [Related]
2. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
4. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection].
Wang YD; Liang QF; Li ZY; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 and Its Therapeutic Applications for Retinal Diseases.
Lin WV; Stout JT; Weng CY
Int Ophthalmol Clin; 2019; 59(1):3-13. PubMed ID: 30585915
[No Abstract] [Full Text] [Related]
6. Gene therapy: In vivo gene editing in non-dividing cells.
Waldron D
Nat Rev Genet; 2017 Jan; 18(1):1. PubMed ID: 27916984
[No Abstract] [Full Text] [Related]
7. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
Luo J
Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
[No Abstract] [Full Text] [Related]
8. Cas9 immunity creates challenges for CRISPR gene editing therapies.
Crudele JM; Chamberlain JS
Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
Duroux-Richard I; Giovannangeli C; Apparailly F
Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
[No Abstract] [Full Text] [Related]
10. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
11. [Research progress of CRISPR-Cas9 system for gene therapy].
Zhan C; Xia X
Sheng Wu Gong Cheng Xue Bao; 2016 Jul; 32(7):861-869. PubMed ID: 29019208
[TBL] [Abstract][Full Text] [Related]
12. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
13. A toolmaker's perspective on CRISPR-directed gene editing as a therapeutic strategy for leukemia and beyond.
Kmiec EB; Bloh K
Expert Rev Hematol; 2021 Jul; 14(7):587-592. PubMed ID: 34047246
[No Abstract] [Full Text] [Related]
14. Genetic engineering: Chemical control for CRISPR editing.
Hilton IB; Gersbach CA
Nat Chem Biol; 2017 Jan; 13(1):2-3. PubMed ID: 27820804
[No Abstract] [Full Text] [Related]
15. Genome editing: CRISPR-Cas becoming more human.
Baumann K
Nat Rev Mol Cell Biol; 2017 Oct; 18(10):591. PubMed ID: 28811667
[No Abstract] [Full Text] [Related]
16. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
17. Genome editing: The efficient tool CRISPR-Cpf1.
Mahfouz MM
Nat Plants; 2017 Mar; 3():17028. PubMed ID: 28260792
[No Abstract] [Full Text] [Related]
18. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas in its prime.
Zlotorynski E
Nat Rev Mol Cell Biol; 2019 Dec; 20(12):718-719. PubMed ID: 31685954
[No Abstract] [Full Text] [Related]
20. Weakly immunogenic CRISPR therapies.
Wilson EA; Anderson KS
Nat Biomed Eng; 2019 Oct; 3(10):761-762. PubMed ID: 31591524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
